product name AZD3264
Description: AZD3264 is a novel and potent IKK2 inhibitor. AZD3264 is currently in preclinical development for the potential treatment of inflammatory diseases such as asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis. Suppression of IKK2 has been identified as a potential therapeutic option to treat cancer and inflammatory diseases, including asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis.
References: Org. Process Res. Dev. 2014, 18, 646−651.
441.5
Formula
C21H23N5O4S
CAS No.
1609281-86-8
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 88 mg/mL (199.3 mM)
Water: <1 mg/mL
Ethanol: 2 mg/mL (4.5 mM)
Solubility (In vivo)
Synonyms
other peoduct :
| In Vitro |
In vitro activity: AZD3264, by inhibiting IKK2, was currently in preclinical development for the potential treatment of inflammatory diseases such as asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis. Kinase Assay: Cell Assay: 1AZD3264, by inhibiting IKK2, was currently in preclinical development for the potential treatment of inflammatory diseases such as asthma, chronic pulmonary obstructive disorder (COPD) and rheumatoid arthritis. |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | Org. Process Res. Dev. 2014, 18, 646−651. |
